Neuropeptide Y Y1 receptor antagonist (BIBP 3226) attenuates stress evoked tachycardia in conscious spontaneously hypertensive rats

Cardiovascular Drugs and Therapy

Volumn 11, Issue 6, 1997, Pages 801-806

  Zhang, Weiguo ^a   Lundberg, Jan M ^a   Thorén, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cardiovascular regulation; Neuropeptide Y; SHR; Stress; Tachycardia; Y1 receptor antagonist

Indexed keywords

CATECHOLAMINE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; MENTAL STRESS; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TACHYCARDIA;

ANIMALS; ANTI-ANXIETY AGENTS; ARGININE; BLOOD PRESSURE; EPINEPHRINE; HEART RATE; HYPERTENSION; NOREPINEPHRINE; RATS; RATS, INBRED SHR; RECEPTORS, NEUROPEPTIDE Y; STRESS, PSYCHOLOGICAL;

EID: 0031469621     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007726626924     Document Type: Article

References (36)

1. Potter EK. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther 1988;37:251-273.
2. Lundberg JM, Pernow J, Lacroix JS. Neuropeptide Y: Sympathetic cotransmitter and modulator? NIPS 1989;4:13-17.
3. Walker P, Grouzmann E, Burnier M, Waeber B. The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci 1991;12:111-115.
4. Ganten D, Paul M, Lang RE. The role of neuropeptides in cardiovascular regulation. Cardiovasc Drugs Ther 1991; 5:119-130.
5. Heilig M, Widerlov E. Neurobiological and clinical aspects of neuropeptide Y. Crit Rev Neurobiol 1995;9:115-136.
6. Munglani R, Hudspith MJ, Hunt SP. The therapeutic potential of neuropeptide Y - analgesia, anxiolylic and antihypertensive. Drugs 1996;52:371-389.
7. Doods HN, Wieland HA, Engel W, et al. BIBP 3226, the first selective neuropeptide Y1 receptor antagonist - a review of its pharmacological properties. Regul Pept 1996;65:71-77.
8. McDermott BJ, Millar BC, Piper HM. Cardiovascular effects of neuropeptide Y: Receptor interactions and cellular mechanisms. Cardiovasc Res 1993;27:893-905.
9. Edvinsson L, Ekblad E, Håkanson R, Wahlestedt C. Neuropeptide Y potentiates the effects of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 1984 83:519-525.
10. Michel M. Receptor for neuropeptide Y: Multiple subtypes and multiple second messengers. Trends Pharmacol Sci 1991;12:389-394.
11. Lundberg JM, Martinsson A, Theodorsson-Norheim E, Svedenhag E, Ekblom B, Hjemdahl P. Co-release of neuropeptide Y and catecholamine during physical exercise in man. Biochem Biophys Res Commun 1985;133:30-36.
12. Sundler F, Böttcher G, Ekblad E, Hakanson. PP, PYY, and NPY. Occurrence and distribution in the periphery. In: Colmers WF, Wahlestedt C, eds. The Biology of Neuropeptide Y and Related Peptides. New Jersey: Humana Press, 1993: 157-196.
13. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.
14. Ogawa T, Kitamura K, Kawamoto M, Eto T, Tanaka K. Increased immunoreactive neuropeptide Y in platelets of spontaneously hypertensive rats (SHR). Biochem Biophys Res Commun 1989;165:1399-1405.
15. Ogawa T, Kitamura K, Kangawa K, Matsuo H, Eto T. Platelet neuropeptide Y in spontaneously hypertensive rats. J Hypertens 1992;10:765-771.
16. Zukowska-Grojec Z, Golezynska M, Shen GH, et al. Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr Nephrol 1993;7:845-852.
17. Howe PRC, Rogers PF, Morris MJ, Chalmers JP, Smith RM. Plasma catecholamine and neuropeptide-Y as indices of sympathetic nerve activity in normotensive and strokeprone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1986;8:1113-1121.
18. Miller DM, Tessel R. Age-dependent hyperresponsiveness of spontaneously hypertensive rats to the presser effects of intravenous neuropeptide Y (NPY): Role of mode of peptide administration and plasma NPY-like immunoreactivity. J Cardiovasc Pharmacol 1991;18:647-656.
19. Lundberg JM, Franco-Cereceda A, Hemsen A, Lacroix JS, Pernow J. Pharmacology of noradrenaline and neuropeptide tyrosine (NPY)-mediated sympathetic cotransmission. Fundam Clin Pharmacol 1990;4:373-391.
20. Myers AK, Farhat MY, Shen GH, Debinski W, Wahlestedt C, Zukowska-Grojec Z. Platelets as a source and site of action for neuropeptide Y. Ann NY Acad Sci 1990;611:408-411.
21. Zukowska-Grojec Z, Wahlestedt C. Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Wahlestedt C, eds. The Biology of Neuropeptide Y and Related Peptides. New Jersey: Humana Press, 1993:315-318.
22. Rudolf K, Eberlein W, Engel W, et al. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP 3226. Eur J Pharmacol 1994;271:R11-R13.
23. Serradeil-Le Gal C, Valette G, Rouby PE, et al. SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett 1995;362:192-196.
24. 3H]BIBP 3226. Eur J Pharmacol 1995;278:239-242.
25. Lundberg JM, Modin A. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharmacol 1995;116:2971-2982.
26. Hallbäck M, Folkow B. Cardiovascular responses to acute mental "stress" in spontaneously hypertensive rats. Acta Physiol Scand 1974;90:684-698.
27. Lundin S, Hallbäck-Nordlander M. Background of hyperkinetic circulatory state in young hypertensive rats. Cardiovase Res 1980;14:561-567.
28. Lundin S, Thoren P. Renal function and sympathetic activity in spontaneously hypertensive rats (SHR) during mental stress. Acta Physiol Scand 1982;115:115-129.
29. Lundin S, Kicksten SE, Thoren P. Interaction between "mental stress" and baroreceptor reflexes concerning effects on heart rate, mean arterial pressure and renal sympathetic activity in conscious spontaneously hypertensive rats. Acta Physiol Scand 1984;120:273-281.
30. Erisson BM, Persson BA. Determination of catecholamine in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J Chromatogr 1982; 228:143-154.
31. Doods HN, Wienen W, Entzeroth M, et al. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exper Ther 1995;275:136-142.
32. Jern S, Bergbrant A, Hedner T, Hansson L. Enhanced pressure responses to experimental and daily-life stress in borderline hypertension. J Hypertens 1995;13:69-79.
33. McCarthy R, Kopin IJ. Alterations in plasma catecholamine and behavior during acute stress in spontaneously hypertensive and Wistar-Kyoto normotensive rats. Life Sci 1978;22:997-1006.
34. Thoren P. Efferent renal nerve traffic in the spontaneously hypertensive rat. Clin Exper Hypertens 1987;A9(Suppl. 1) 259-79.
35. Allen JM, Bircham PMM, Bloom SR, Edwards AV. Release of neuropeptide Y in response to splanchnic nerve stimulation in the conscious calf. J Physiol (Lond) 1984;357:401-406.
36. Sun XY, Zhao XH, Erlinge DR, Edvinsson L, Fallgren B, Wahlestedt C, Hedner T. Effects of phosphorothioated neuropeptide Y Y1-receptor antisense oligodeoxynucleotide in conscious rats and in human vessels. Br J Pharmacol 1996;118:1331-1136.